Endocrine Abstracts

Pheochromocytomas and paragangliomas (PPGL) are rare neuroendocrine tumors derived from chromaffin cells of the adrenal medulla and paraganglia of the autonomic nervous system, respectively. Despite a common origin, these tumors are quite heterogeneous in terms of driver mutations, copy number alterations and activated downstream-signaling pathways. Genome wide expression analysis has identified at least three main tumor clusters: a pseudo-hypoxic cluster, one with activation ...

Pheochromocytoma and Paraganglioma, collectively referred to as PPGLs, are rare, mostly benign neuroendocrine tumors arising from chromaffin cells of the adrenal gland or of extra-adrenal sites, respectively. Surgery is the first-line therapy for localized PPGLs. However, up to 17% of PPGLs show metastatic spread, and for these cases there is no curative treatment. Therefore, the identification of novel therapeutic approaches for advanced PPGLs is highly clinically relevant. W...

Non-functioning pituitary adenomas (NFPAs), mainly gonadotroph pituitary adenomas (GPAs), are the second most common type of PAs. Given the lack of symptoms secondary to hormone hypersecretion, NFPAs are often diagnosed when they cause mass effects. At this stage they are invasive (50% of cases), they cannot be completely resected and often recur. Despite their frequency, no standard of care drug treatment currently exists for these tumors. SSAs (somatostatin agonists) like oc...

Background: Invasive nonfunctioning (NF) pituitary neuroendocrine tumors (PitNETs) are non-resectable neoplasms associated to frequent relapse and significant comorbidities. As current treatments often fail against NF-PitNETs, identifying actionable therapeutic targets is essential. We focused on the angiopoietin-2 (Angpt2)/Tie2 axis, usually active in endothelial cells (ECs).Methods: ANGPT2 plasma levels in NF-PitNET patients and healthy controls were m...